ENDPQ Stock price prediction

Endo International ENDPQ Stock Price Prediction — 2023, 2025, 2030

Introduction

Hey there! If you are struggling to find the best Endo International ENDPQ Stock Price Prediction all over the internet, then smile because now your struggle is about to end as you scroll down to the article below. In this article, we have tried to provide you with the best prediction on the stock after doing extensive research on it. We have also made use of AI tools and the CAGR technique to get more refined predictions. As you read the article below, you will also get all the related information on the stock to help you make a more informed decision about your investment.

Endo International plc is a global specialty pharmaceutical company that focuses on developing, manufacturing, and distributing branded and generic pharmaceuticals, as well as medical devices. The company was founded in 1997 and is headquartered in Dublin, Ireland.

Endo’s portfolio of products includes drugs for pain management, urology, oncology, endocrinology, and other therapeutic areas. The company operates through various subsidiaries, including Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, and SOMAR.

Endo has a global presence with operations in North America, Latin America, Europe, the Middle East, and Asia Pacific. The company’s mission is to improve the lives of patients by developing innovative healthcare solutions that address unmet medical needs.

Endo’s stock is traded on the NASDAQ stock exchange under the ticker symbol ENDP. The company has faced some challenges in recent years, including lawsuits related to the marketing of its opioid products and the loss of patent protection for some of its key products. However, the company has continued to invest in research and development and strategic acquisitions to drive growth and innovation in the pharmaceutical industry.

What Is Endo International Stock?

Endo International plc (ENDP) is a pharmaceutical company that develops, manufactures, and distributes generic and branded pharmaceuticals, as well as medical devices. The company’s products are used in a range of therapeutic areas, including pain management, urology, oncology, and endocrinology. ENDP is listed on the NASDAQ stock exchange and its stock price can fluctuate based on a variety of factors such as financial performance, industry trends, regulatory changes, and global economic conditions.

Endo International Stock Current Price

The current price for Endo International PLC is $0.015 as of 3/7/2023 with −0.0025 (14.29%) in last 24 hr.

Graph

Endo International Stock Prediction– 2023, 2025, 2030

YearsMinimum PriceAverage PriceMaximum Price
2023$0.010$0.38$0.75
2024$0.0066$0.250$0.495
2025$0.0043$0.165$0.302
2026$0.0028$0.108$0.199
2027$0.0018$0.071$0.131
2028$0.0011$0.046$0.086
2029$0.0007$0.030$0.056
2030$0.0004$0.0198$0.036
Table on Endo International Stock Price Prediction

Endo International Stock Price Prediction For Every Upcoming Year

For 2023:

In 2023, the prediction for maximum price is $0.75, minimum price is $0.010 and the average price is around $0.38.

For 2024:

The predicted forecast for 2024 is: maximum price $0.495, minimum price $0.0066 and the average price $0.250. This prediction for Endo International stock shows that it has a declining trend in this year.

For 2025:

The Endo International stock continues to have its downward trend in this year too. The average price for the stock is predicted to be around $0.165, the minimum price will be $0.0043 whereas the maximum price is predicted to be $0.302.

For 2026:

In 2026, Endo International doesn’t perform well with an average price to be around $0.108 and the stock ranges between $0.0028 to $0.199.

For 2027:

Endo International stock continues to show its downward trend in this year again. The stock ranges between the price $0.0018 to $0.131 with an average price being around $0.071.

For 2028:

2028 has also been not a great year for Endo International stock. The stock continues to fall in this year too with an average price of the stock being around $0.046, maximum price $0.086 and minimum price $0.0011.

For 2029:

In 2029, the stock price for Endo International ranges in between $0.0007$0.056 with an average price of the stock being around $0.030. According to the prediction of this year, it clearly seems that the company do well.

For 2030:

The predicted forecast for 2030 is: maximum price $0.036, minimum price $0.0004 and the average price $0.0198. This prediction for Endo International stock shows that it has a declining trend in this year too.

Endo International Stock Technical Analysis

Endo International’s stock price has been in a downtrend since 2015, with the stock experiencing significant volatility over the past few years. Here are some key technical indicators for ENDP:

  • Moving averages: The stock’s 50-day moving average was below the 200-day moving average, which is a bearish signal.
  • Relative Strength Index (RSI): The RSI for Endo International was below 50, which suggests that the stock may be oversold and due for a potential rebound.
  • MACD: The MACD for Endo International was negative, indicating a bearish trend.

In September 2021, Endo International’s stock price was trading near the lower end of its 52-week range, which may suggest that the stock is undervalued. However, the bearish technical indicators suggest that investors may want to exercise caution before entering into a long position in the stock.

Overall, the technical analysis of Endo International suggests that the stock is in a downtrend and may continue to experience volatility in the near term. Investors should carefully consider the risks and potential rewards before making a decision on whether to invest in ENDP.

Endo International Stock Fundamental Analysis

These fundamental analyses of Endo International plc is based on its financial performance and key metrics as of my knowledge cut-off date of September 2021. (Note: This analysis is based on publicly available information and may not reflect the current status of the company.)

Financial Performance:

  • Revenue: Endo International’s revenue for the trailing twelve months ending on June 30, 2021, was $2.7 billion, which represents a decline of 9.2% compared to the previous year.
  • Net Income: The company reported a net income of $197.1 million for the trailing twelve months ending on June 30, 2021, compared to a net loss of $2.8 billion for the previous year.
  • Earnings Per Share (EPS): Endo’s EPS for the trailing twelve months ending on June 30, 2021, was $0.87, compared to a loss per share of $12.54 for the previous year.

Key Metrics:

  • Price-to-Earnings (P/E) Ratio: As of September 2021, Endo International’s P/E ratio was 1.86, which is significantly lower than the industry average of 22.84. This indicates that the company’s stock may be undervalued relative to its earnings.
  • Price-to-Sales (P/S) Ratio: Endo’s P/S ratio was 0.52 as of September 2021, which is lower than the industry average of 4.40. This may suggest that the company’s stock is undervalued relative to its sales.
  • Debt-to-Equity (D/E) Ratio: The company’s D/E ratio was 1.36 as of June 30, 2021, which is higher than the industry average of 0.85. This indicates that the company has a higher level of debt compared to its equity.
  • Return on Equity (ROE): Endo’s ROE for the trailing twelve months ending on June 30, 2021, was 8.0%, which is lower than the industry average of 15.3%. This suggests that the company may not be generating as much profit from shareholder investments as its peers.

Overall, Endo International’s financial performance and key metrics suggest that the company may be undervalued relative to its earnings and sales, but its higher level of debt and lower ROE compared to industry peers may be a cause for concern. As with any investment, investors should carefully consider the risks and potential rewards before making a decision.

Some Related Posts

Conclusion:-

In conclusion, Endo International plc is a global specialty pharmaceutical company that develops, manufactures, and distributes branded and generic pharmaceuticals, as well as medical devices. The company operates through various subsidiaries and has a portfolio of products used in a range of therapeutic areas. Endo’s mission is to improve the lives of patients by developing innovative healthcare solutions that address unmet medical needs.

Although Endo has faced challenges in recent years, the company has continued to invest in research and development and strategic acquisitions to drive growth and innovation. The company’s stock is traded on the NASDAQ stock exchange and its performance can be influenced by a range of factors such as financial performance, regulatory changes, and global economic conditions. Overall, Endo International plc is an important player in the pharmaceutical industry with a focus on improving patient outcomes through innovative healthcare solutions.

FAQs (Frequently Asked Questions)

Q1. Will Endo stock go up?

Ans:- The 1 analysts offering 12-month price forecasts for Endo International PLC have a median target of 1.00, with a high estimate of 1.00 and a low estimate of 1.00. The median estimate represents a +1,324.50% increase from the last price of 0.07.

Q2. Is Endo a good stock to buy?

Ans:- If you are looking for stocks with good returns, Endo International plc stock can be a bad, high-risk 1-year investment option. Endo International plc’s real-time quote equals 0.137 USD on 2023-03-09, but your current investment may be devalued in the future. 

Q3. Is Endo Pharmaceuticals going out of business?

Ans:- Deluged by 3,100 opioid-related lawsuits and billions in debt, Endo filed for bankruptcy in August in New York.

Important Note :- Please note that the predictions presented in this article regarding ENDPQ stock performance are based on analysis conducted by reputable sources and industry experts. These predictions are derived from a combination of extensive research and the utilization of techniques such as Compound Annual Growth Rate (CAGR). While these predictions provide valuable insights, it’s important to remember that the stock market is inherently unpredictable, and actual results may vary. Investors should exercise caution and conduct their own due diligence before making any investment decisions.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top